The European Commission has approved a subcutaneous, or under the skin, route of administration and a new pharmaceutical form (solution for injection) of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.
The European Commission has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.
